- Home
- ZTEK vs COEP Comparison
ZTEK vs COEP Comparison
Compare ZTEK & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | COEP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 7 |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 72.7M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZTEK | COEP |
|---|---|---|
| Price | $0.50 | $15.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 79.6K | 35.3K |
| Earning Date | 02-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $6.32 |
| 52 Week High | $1.84 | $21.41 |
Technical Indicators
Market Signals| Indicator | ZTEK | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 72.54 |
| Support Level | N/A | $10.59 |
| Resistance Level | $0.57 | $19.19 |
| Average True Range (ATR) | 0.04 | 1.01 |
| MACD | -0.00 | 0.48 |
| Stochastic Oscillator | 34.32 | 96.12 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.